Atara biotherapeutics announces third quarter 2021 financial results and operational progress

South san francisco, calif.--(business wire)--atara biotherapeutics, inc. (nasdaq: atra), a leader in t-cell immunotherapy, leveraging its novel allogeneic epstein-barr virus (ebv) t-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today reported financial results for the third quarter 2021, recent business highlights and key catalysts over the next several months. “atara continues to make meaningful progress across our strategic priorities and
ATRA Ratings Summary
ATRA Quant Ranking